Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients.
IGF-1
IGFBP-3
Renal cell carcinoma
genetic risk score
recurrence
survival
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
10
2021
accepted:
04
02
2022
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
epublish
Résumé
Insulin growth-like factor-1 (IGF-1) and its main binding protein insulin growth-like factor binding protein 3 (IGFBP-3) play important roles in cancer development and progression. We hypothesize that circulating IGF-1 and IGFBP-3 may have significant prognostic values in renal cell carcinoma (RCC) patients. We used 1,010 histologically confirmed RCC patients in this case series study to test this hypothesis. We constructed a weighted genetic risk score (GRS) using a large panel of genome-wide association study (GWAS)-identified single nucleotide polymorphisms (SNPs) to predict circulating IGF-1 and IGFBP-3 level, respectively. We analyzed the associations of the GRS with the prognosis of RCC patients using multivariate Cox proportional hazards model. We found significant associations between genetically predicted circulating IGF-1 level, but not IGFBP-3, and RCC prognosis. RCC patients with better prognosis had significantly higher baseline circulating IGF-1 level than those with worse prognosis. Dichotomized at the median value of GRS, patients with high IGF-1 exhibited significantly lower risks of recurrence (HR=0.81, 95% CI, 0.65-0.99, P=0.045) and death (HR=0.74, 95% CI, 0.60-0.91, P=0.004). If patients were dichotomized at the 75% value of GRS, those with the highest quarter of GRS had 27% lower risk of recurrence (OR=0.73, 95% CI, 0.55-0.96, P=0.025) and 34% lower risk of death (OR=0.66, 95% CI, 0.50-0.87, P=0.003) than the other three quarters of patients. High IGF-1/IGFBP-3 ratio was also associated with reduced risks of recurrence and survival. In conclusion, high circulating IGF-1 level and IGF-1/IGFBP-3 ratio at diagnosis is associated with better prognosis in RCC patients.
Types de publication
Journal Article
Langues
eng
Pagination
852-860Informations de copyright
AJCR Copyright © 2022.
Déclaration de conflit d'intérêts
None.
Références
Br J Cancer. 2001 Sep 28;85(7):984-90
pubmed: 11592770
Endocr Relat Cancer. 2015 Oct;22(5):R253-64
pubmed: 26330483
Nat Genet. 2021 Feb;53(2):185-194
pubmed: 33462484
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Methods Mol Biol. 2009;472:57-88
pubmed: 19107429
Carcinogenesis. 2021 Jun 21;42(6):826-830
pubmed: 33852723
Hum Mol Genet. 2012 Jan 15;21(2):456-62
pubmed: 22010048
Lung Cancer. 2006 Nov;54(2):227-34
pubmed: 16935391
Aging Cell. 2016 Oct;15(5):811-24
pubmed: 27329260
Cancer Res. 2020 Sep 15;80(18):4014-4021
pubmed: 32709735
Lancet Oncol. 2010 Jun;11(6):530-42
pubmed: 20472501
Int J Urol. 2005 Jan;12(1):17-28
pubmed: 15661050
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
Eur Urol. 2014 Jul;66(1):77-84
pubmed: 24613583
Gastroenterology. 2020 Apr;158(5):1300-1312.e20
pubmed: 31884074
Clin Cancer Res. 2008 Dec 15;14(24):8263-9
pubmed: 19073970
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
J Clin Oncol. 2016 Oct 20;34(30):3655-3663
pubmed: 27601543
PLoS One. 2012;7(11):e49884
pubmed: 23185474
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Maturitas. 2016 Dec;94:22-29
pubmed: 27823741
J Clin Oncol. 2011 Oct 10;29(29):3892-9
pubmed: 21911725
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
BMC Cancer. 2016 Jul 12;16:453
pubmed: 27405474
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nutrients. 2017 Apr 18;9(4):
pubmed: 28420208
Nat Rev Cancer. 2012 Feb 16;12(3):159-69
pubmed: 22337149
Ann Oncol. 2020 May;31(5):641-649
pubmed: 32169310
Curr Epidemiol Rep. 2018 Jun;5(2):184-196
pubmed: 30034993
Front Oncol. 2020 Aug 19;10:1384
pubmed: 32974138
Int J Cancer. 2013 Feb 1;132(3):625-34
pubmed: 22610826
Pediatr Endocrinol Rev. 2015 Dec;13(2):499-511
pubmed: 26841638
Int J Cancer. 2021 May 1;148(9):2274-2288
pubmed: 33252839
Lancet. 2004 Apr 24;363(9418):1346-53
pubmed: 15110491
Urol Oncol. 2016 Jun;34(6):258.e15-22
pubmed: 26803435
Methods Mol Biol. 2009;472:191-215
pubmed: 19107434
Cancer Med. 2020 Sep;9(18):6836-6842
pubmed: 32717139
Oncology. 2020;98(12):836-846
pubmed: 33027788
Nat Rev Endocrinol. 2011 Jan;7(1):11-24
pubmed: 20956999
Acta Oncol. 2004;43(8):744-8
pubmed: 15764220
Endocr Rev. 1995 Feb;16(1):3-34
pubmed: 7758431
Expert Rev Anticancer Ther. 2018 Jul;18(7):663-671
pubmed: 29707987
Br J Cancer. 2010 Jun 29;103(1):132-5
pubmed: 20517306
Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2332-2342
pubmed: 32856611
Urol Oncol. 2018 Feb;36(2):79.e1-79.e10
pubmed: 29110942
Lancet Oncol. 2015 Jun;16(6):676-85
pubmed: 25979595
Cancer Causes Control. 2017 Jul;28(7):801-807
pubmed: 28484923
Int J Cancer. 2010 Apr 1;126(7):1702-15
pubmed: 19810099
Front Endocrinol (Lausanne). 2018 Apr 09;9:117
pubmed: 29686648
J Cell Commun Signal. 2019 Sep;13(3):381-394
pubmed: 30929166